Biotechnology: A sector built around practical scientific innovation

Genflow Biosciences Plc

Biotechnology uses living organisms, cells and biological processes to create products and solve practical problems. This is a sector where scientific progress can become commercial opportunity across healthcare, agriculture, industry and environmental applications.

At its simplest, biotechnology applies biology to product development. This can include using microorganisms to produce medicines, improving crops through genetic techniques, developing diagnostic tools, or creating cleaner industrial processes. The common thread is the use of biological systems to improve how products are made, how diseases are treated, or how resources are managed.

Healthcare is one of the most visible areas of biotechnology. Companies in this space may work on new medicines, vaccines, gene therapies or diagnostic tests. These products can address clear market needs, particularly where existing treatments are limited.

Biotechnology also has relevance beyond medicine. In agriculture, it can help improve crop performance, increase resistance to pests and support more efficient food production. In industrial settings, biological processes can be used to make chemicals, materials and fuels in ways that may reduce waste or environmental impact.

Genflow Biosciences plc (LON:GENF, OTCQB:GENFF, FRA:WQ5) is a UK-based biotech firm with R&D facilities in Belgium focused on developing novel therapeutic approaches that potentially halt or slow the aging process in humans and dogs supporting longer, healthier lives

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Genflow reports biological age reductions in dog gene therapy study

Genflow Biosciences reports reductions in measured epigenetic age in dogs receiving SIRT6c gene therapy, selecting intravenous plasmid DNA as its lead veterinary delivery method while further follow-up continues.

Genflow Biosciences secures Japanese patent and expands animal health partnerships

Genflow Biosciences has secured Japanese patent allowance for its SIRT6 gene therapy, with all 16 claims approved, and signed additional confidentiality agreements with animal health companies. Its regional grant application is under review, with no impact on financial guidance expected.

Genflow Biosciences: SLAB-VET Results Put SIRT6 Partnering and Human Therapies in Focus (video)

Genflow Biosciences’ latest SLAB-VET-001 results are sharpening the commercial case for its SIRT6c platform. CEO Dr Eric Leire discusses the signals seen in naturally aged dogs, why pDNA is leading the veterinary programme, growing interest from animal health companies and how progress could feed into Genflow’s human sarcopenia strategy.

Genflow Biosciences examines the role of genes in ageing

Genflow Biosciences is investigating a SIRT6 gene variant associated with longevity as part of its research into therapies targeting biological ageing.

Genflow reports SIRT6 gene therapy results in aged dogs

Genflow reports reduced epigenetic age in dogs treated with its SIRT6c gene therapy, with pDNA selected as the lead delivery method for its veterinary programme.

Genflow completes SLAB trial as human and animal health programmes advance

Genflow Biosciences completed its SLAB canine healthspan and sarcopenia trial in H1 2026, with the company reporting safety and tolerability data for GF-1004. The group also advanced its glaucoma, MASH, Mitosir and Exofastrack programmes while ending the period with £632,553 in cash.

Search